These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7892547)

  • 1. [Activity profile of beta blockers].
    Drexel H
    Praxis (Bern 1994); 1995 Mar; 84(10):278-80. PubMed ID: 7892547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockers as antiarrhythmic agents.
    Zicha S; Tsuji Y; Shiroshita-Takeshita A; Nattel S
    Handb Exp Pharmacol; 2006; (171):235-66. PubMed ID: 16610347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of beta-blockers: classical aspects and recent developments.
    Haeusler G
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S1-9. PubMed ID: 11527109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The beta 2-pseudoselectivity of ISA (intrinsic sympathomimetic action)--consequences for differential therapy with beta-blockers with and without ISA?].
    Werdan K; Reithmann C
    Dtsch Med Wochenschr; 1988 Feb; 113(7):272-4. PubMed ID: 2893724
    [No Abstract]   [Full Text] [Related]  

  • 6. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.
    Magnusson Y; Levin MC; Eggertsen R; Nyström E; Mobini R; Schaufelberger M; Andersson B
    Clin Pharmacol Ther; 2005 Sep; 78(3):221-31. PubMed ID: 16153393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of intrinsic sympathomimetic activity on beta-blocker efficacy for treatment of neurocardiogenic syncope.
    Cohen TJ; Cayenne S; Black M; Doolittle S; Ibrahim B; Quan W
    J Invasive Cardiol; 1999 Jul; 11(7):457-60. PubMed ID: 10745573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of beta-blockade with beta-1-selectivity or intrinsic sympathomimetic activity on some cardiorespiratory responses to exercise.
    Yonga GO; Oyuga HW; Njeru EK
    East Afr Med J; 1993 Jul; 70(7):405-8. PubMed ID: 7904931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of beta blockers: a class action or individual pharmacologic spectrum?
    Harrison DC
    Circulation; 1983 Jun; 67(6 Pt 2):I77-82. PubMed ID: 6133648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
    Mehvar R; Brocks DR
    J Pharm Pharm Sci; 2001; 4(2):185-200. PubMed ID: 11466176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacology of adrenergic beta receptor blockaders].
    Román O
    Rev Med Chil; 1991 May; 119(5):577-83. PubMed ID: 1688229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving mechanisms of action of beta blockers: focus on nebivolol.
    Mason RP; Giles TD; Sowers JR
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are we misunderstanding beta-blockers.
    Cruickshank JM
    Int J Cardiol; 2007 Aug; 120(1):10-27. PubMed ID: 17433471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of beta-blockade with beta-1-selectivity or intrinsic sympathomimetic activity on some metabolic responses to exercise.
    Yonga GO; Oyuga HW; Njeru EK
    East Afr Med J; 1993 Jul; 70(7):402-4. PubMed ID: 7904930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and therapeutic properties of an ideal beta-blocker.
    Taylor SH
    J Int Med Res; 1988; 16 Suppl 1():8A-16A. PubMed ID: 2906020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation between pharmacokinetics and dynamics: explanation of clinical aspects exemplified by beta-receptor blockers].
    Palm D; Wellstein A; Schloos J; Belz GG
    Verh Dtsch Ges Inn Med; 1991; 97():338-42. PubMed ID: 1687299
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of intrinsic sympathomimetic activity for beta blockers.
    Jaillon P
    Am J Cardiol; 1990 Sep; 66(9):21C-23C. PubMed ID: 1977302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers, dyslipidemia, and coronary artery disease. A reassessment.
    Burris JF
    Arch Intern Med; 1993 Sep; 153(18):2085-92. PubMed ID: 8104394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.